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ABSTRACT  
OBJECTIVE: This study aimed to investigate the neural correlates of psychotic-like experiences in 
youth on measures of inhibitory control, reward anticipation and emotion processing. A 
secondary aim was to test whether these neuro-functional correlates of risk were predictive of 
psychotic symptoms 2 years later. 
METHOD: Functional imaging response to three paradigms: the Stop-Signal, Monetary Incentive 
Delay, and Faces tasks was collected in youth at age 14, as part of the IMAGEN study. At 
baseline, youth from London and Dublin sites were assessed on psychotic-like experiences and 
those reporting significant experiences were compared with matched controls. Significant brain 
activity differences between the groups were used to predict, with cross-validation, the 
presence of psychotic symptoms in the context of mood fluctuation at age 16, assessed in the 
full sample. These prediction analyses were conducted with the London-Dublin subsample 
(N=246) and the full sample (N=1196). 
RESULTS: Youth reporting psychotic-like experiences showed increased hippocampus/amygdala 
activity during neutral faces processing and reduced dorsolateral prefrontal activity during failed 
inhibition relative to controls. The most prominent region for classifying 16-year olds with mood 
fluctuation and psychotic symptoms relative to the control groups (those with mood 
fluctuations but no psychotic symptoms and those with no mood symptoms) included 
hyperactivation of the hippocampus/amygdala, when controlling for baseline psychotic-like 
experiences and cannabis use. 
CONCLUSIONS: The results stress the importance of the limbic network’s increased response to 
neutral facial stimuli as a marker of the extended psychosis phenotype. These findings might 
help to guide early intervention strategies for at-risk youth. 
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INTRODUCTION  
There is evidence of a continuity between clinical and subclinical phenotypes of psychosis that is 
measurable in the general population (1) and in individuals with a psychiatric diagnosis (2). On a 
clinical level, individual differences in psychosis proneness are expressed across a number of 
psychiatric conditions besides schizophrenia, namely mood, anxiety, eating, impulse control, 
and substance use disorders (2). At a subclinical level this liability is characterized by 
“attenuated” or “brief” psychotic symptoms that might not co-exist with other diagnostic 
criteria (frequency and intensity) to meet full diagnosis, yet sufficient impairment is observed to 
motivate treatment seeking (3). This clinical high-risk state has been shown to be a robust risk 
factor for progression to clinically-significant psychiatric disorders (4), but does not necessarily 
predict to one specific disorder and instead is predictive of a number of psychopathologies that 
include psychotic symptoms (5). 
At the far end of the extended psychosis continuum are children/adolescents from the 
community reporting psychotic-like experiences (i.e., perceptual abnormalities and delusional 
thoughts) prior to the onset of more impairing psychotic symptoms. These preclinical 
experiences, even though they are common in children/young adolescents (7 to 23% (6)), are 
associated with increased risk for psychotic or Axis I disorders over the longer term (6, 7). 
Studying young adolescents prone to such experiences will help to identify etiologic processes 
implicated in psychosis proneness, without the confounds of diverse risk factors and iatrogenic 
effects, such as substance misuse, medication and social impairment (8). Investigating the 
neural correlates of this preclinical psychosis proneness on cognitive functioning can shed light 
on early altered neural processes prior to significant cognitive impairments.   
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However, the vast majority of functional magnetic resonance imaging (fMRI) studies have 
focused on adults with a clinical risk to psychosis, not on young adolescents reporting psychotic-
like experiences. These studies have mostly investigated the neural circuits implicated in 
executive functioning, social cognition and reinforcement learning. Recent fMRI studies in 
individuals with psychosis-spectrum symptoms have shown significant reduced activation in the 
dorso-lateral prefrontal cortex (dlPFC) during executive functioning (e.g., working memory, 
inhibitory control) relative to low-risk controls (9, 10). These results are consistent with findings 
of dlPFC hypoactivation in patients with clinical diagnoses of psychosis or bipolar disorder on 
tasks of working memory and response inhibition (11, 12), suggesting that the brain markers 
associated with psychosis proneness cross diagnostic boundaries.    
Social cognition which encompasses emotion processing and theory of mind processes has also 
been identified as a domain which might differentiate individuals at clinical risk for psychosis 
from low-risk individuals (13). Neuroimaging studies show that the experience of high arousal 
negative emotions is associated, in individuals at clinical risk relative to healthy controls, with 
both reduced (14) and increased activation of fronto-limbic areas (9), depending on the contrast 
used (15), while viewing neutral material is more consistently associated with increased 
activation of this network (14, 16).  
Another core feature of psychosis, dysfunctional reinforcement learning, was shown to be 
shared with distinct diagnostic categories such as major depressive and bipolar disorders (17). A 
recent meta-analysis of fMRI studies has demonstrated that psychosis spectrum disorders are 
associated with a blunted response from the ventral striatum during anticipation of reward, 
which might explain why patients demonstrate impaired learning of stimulus-reinforcement 
associations (18). Functional MRI studies with clinically at-risk individuals have shown modest 
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reduced activity in fronto-striatal regions during reward anticipation, relative to controls (19, 
20).  
Among the very few neuroimaging studies investigating the early neural correlates of preclinical 
psychosis proneness prior to the onset of more impairing psychotic symptoms, Modinos et al. 
(21, 22) found that community youth self-reporting psychotic-like experiences had reduced 
activation of the medial prefrontal cortex, insula and amygdala during passive viewing and 
reappraisal of negative pictures relative to low-risk youth. In a quite young sample of 11- to 13-
year olds reporting these experiences, Jacobson et al. (23) observed reduced activity in 
prefrontal and temporal regions during a response inhibition task. However, the sample was 
small (11 in the at-risk group). Consequently, we intended to extend these findings in another 
community sample of young adolescents with psychotic-like experiences. Of note, considering 
that psychotic-like experiences are, for most individuals, transient and not persistent (1), it is 
crucial to understand to what extent these early neural abnormalities relate to a subsequent 
psychosis vulnerability in terms of clinically validated symptoms.  
The primary aim of the present exploratory study was to identify brain correlates of psychotic-
like experiences in youth prior to exposure to regular substance use on fMRI measures of 
emotion processing, inhibitory control and reward anticipation using data from the IMAGEN 
study, in which two sites, London and Dublin, assessed these preclinical experiences to 
participants when they were 14. The secondary aim was to validate whether these brain 
correlates predicted emergence of psychotic symptoms in the context of mood fluctuation 
symptoms at age 16 in the full IMAGEN sample. We hypothesized that psychotic-like 
experiences would be associated with reduced activity in the executive network during response 
inhibition, altered activity in fronto-limbic regions during processing of emotional and non-
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emotional stimuli as well as modest reduced ventral striatum activity during anticipation of 
reward.  
 
METHODS 
Participants  
2257 14-year old adolescents were recruited through high schools in the large European 
multicenter IMAGEN study from 8 sites across the United Kingdom, Ireland, France and 
Germany. Parents and adolescents gave written informed consent to the study procedures. All 
procedures were approved by each local institutional ethics committee. A detailed description 
of the study recruitment and assessment procedure, exclusion criteria, data storage and safety, 
as well as imaging acquisition protocol may be found elsewhere (24).  
Measures 
For a more detailed description of the study measures, see the online data supplement. 
Psychotic-like experiences 
At baseline, 14-year olds from London and Dublin completed the self-report Adolescent 
Psychotic-Like Symptoms Screener (25), which contains 7 items evaluating perceptual 
abnormalities and delusional thoughts in the past 6 months. Participants were asked to rate 
their responses to different statements on a 1-point scale (0=not true, 0.5=somewhat true, 
1=certainly true). Based on Cannon’s team (23, 25) previous studies, to identify youth with 
significant psychotic-like experiences, we used the following criteria: a total score ≥2 and a score 
≥0.5 on the auditory hallucination (this item revealed 88% probability of predicting which 
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individuals would be classified as “at-risk”, as determined by consensus ratings from the 
Structured Interview for Prodromal Syndromes).  
Among 410 adolescents [mean (SD), 14.3 (0.4) years old; 51.7% girls] from London and Dublin 
sites, 300 had complete fMRI and behavioral information. Among them, 27 were classified as 
having significant psychotic-like experiences. None had yet started using cannabis and they 
reported minimal alcohol and cigarette use (<3-5 times in the previous year). Using an in-house 
groupwise matching script designed by the IMAGEN consortium, the group was matched (on 
sex, handedness, imaging site, general IQ and puberty development) to a control group 5 times 
larger (135 adolescents) which included those with a total score ≤ 1 and a score of 0 on the 
auditory hallucination question.  
Psychotic symptoms at age 16 
For the secondary objective of the study, psychotic symptoms were evaluated with the Self-
Report Development and Well-Being Assessment interview (www.dawba.com) (26), a computer-
based package of questionnaires designed to generate DSM-IV-TR psychiatric diagnoses for 5- to 
16-year olds. While the schizophrenia module was not administered to participants at age 16, 
the bipolar module was more developmentally appropriate for this age group, and therefore 
all participants answered initial screening questions assessing mood dysregulation (“rapid 
mood changes” and “abnormally high mood”), and if positive, they were then asked three 
specific items assessing the presence of visual and auditory hallucinations and delusional beliefs. 
Among the 300 individuals from London and Dublin with complete baseline assessments, 246 
(82.0%) completed the bipolar module at age 16 and were further divided into three groups: 
those who endorsed mood dysregulation plus hallucinatory/delusional symptoms (i.e., group 
with mood and psychotic symptoms, N=12), those reporting mood dysregulation without 
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hallucinatory/delusional symptoms (i.e., group with mood symptoms only, N=80) and those who 
did not endorse the mood dysregulation criteria (i.e., no mood symptoms group, N=154). 
Additionally, we conducted similar analyses on the full IMAGEN sample: among the 1602 
participants re-assessed at 16 years old, 1196 had complete fMRI and behavioral information 
and were divided into three groups: those with mood and psychotic symptoms (N=72), those 
with mood symptoms only (N=451), and those without any mood symptoms (N=673).  
Neuroimaging tasks 
We report results from three task-based fMRI paradigms: the Faces task to assess emotional 
processing, the Stop-Signal Task to evaluate motor inhibitory control and a modified version of 
the Monetary Incentive Delay Task to examine reward anticipation. The block design Faces task, 
known to elicit prefrontal and amygdala activations (27), uses video clips displaying a neutral 
expression progressively turning into angry or a second neutral expression. A control condition 
displays expanding/contracting circles. In the event-related adaptation of the Stop-Signal Task 
used to measure activation of the fronto-striatal network (28), a motor response to high 
frequency go signals (80% of trials) has to be inhibited when infrequently and unexpectedly (in 
randomised 20% of trials), a stop signal appears after the go signal. In the modified Monetary 
Incentive Delay task, participants had to respond to a target in order to win a previously 
indicated amount of points (3 trial types: no win, small win and large win). In the anticipation 
phase, which elicits striatal and medial prefrontal activity (29), participants were presented with 
cues signaling the amount of reward that could be won in a given trial. 
Data analysis 
fMRI 
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To test activity differences between the group reporting or not psychotic-like experiences on 
each of the contrasts of interests (Faces: angry vs neutral and neutral vs control; Stop-Signal: 
stop success vs baseline and stop failure vs baseline; Monetary Incentive Delay: anticipation of 
large reward vs no reward), we conducted two-sample t tests, using a whole-brain approach in 
SPM8 (Wellcome Trust Centre for Neuroimaging). Following Eklund et al. (30) recommendations 
for controlling type 1 error, significant voxels were required to be part of cluster of more than 
24 contiguous voxels giving a 0.05% probability of a cluster surviving due to chance (AFNI’s 
3dClustSim). For our secondary objective, we used a more liberal threshold: significant voxels 
were required to be part of cluster of more than 10 contiguous voxels. Then, we created 
regions-of-interest based on the regions’ coordinates and extracted the mean contrast value 
(betas) for each region of interest and for each subject.  
Machine learning procedure 
For our secondary objective, we aimed to classify youth according to 16-years old psychotic 
outcomes with fMRI information. We conducted cross-validated logistic regressions with elastic-
net regularization to model this relationship. Cross-validation is used to evaluate how well a 
predictive model generalizes to out-of-sample observations. On one hand, leave-one-out cross-
validations were used during classification of the groups within the smaller London-Dublin 
subsample; on the other hand, k(10)-fold cross-validations were used during classification of the 
groups within the full sample. Cross-validation analysis within the London-Dublin subsample 
allowed to test the predictive capacity of the brain markers while controlling for baseline 
psychotic-like experiences. Considering that the sample size of the groups was much larger in 
the full sample, we were able to control for more predictors such as developmental risk factors 
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for psychotic symptoms (i.e., cannabis, alcohol and cigarette use, as well as internalizing and 
externalizing behaviors (31)), gathered at age 14.  
Elastic-net regularization is used to achieve better prediction performance by penalizing the 
regression coefficients in an attempt to minimize overfit. Elastic-net regularization is an example 
of a sparse regression method, which imposes a hybrid of both L1- and L2-norm penalties (i.e., 
penalties on the absolute (L1-norm) and squared values of the regression coefficients (L2-
norm)). Model performance was evaluated using the area under the curve (AUC) of the receiver-
operating characteristic (ROC), which quantifies the predicted sensitivity (true positive rate) as a 
function of false positive rate (1-specificity). 
 
RESULTS 
Demographic and clinical information of the groups at age 14 
Reported in Table 1 are the means of the variables used as matching parameters between the 
27 adolescents with and the 135 matched controls without psychotic-like experiences (no 
significant differences between the groups). Furthermore, the groups were not different on age, 
as well as alcohol, cigarette and cannabis use in the previous year.  
Task activation differences between the groups 
Between-group differences were present in small clusters in the three tasks (Table 2). Only two 
significant clusters of activity differences survived the cluster-corrected threshold of 24 
contiguous voxels: a hyperactivation of the right anterior hippocampus/amygdala during passive 
viewing of neutral/ambiguous faces and a reduced activity in the right dlPFC during failure to 
inhibit a motor response in youth with psychotic-like experiences (Figure 1).  
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Prediction of psychotic-related symptoms at age 16 
First, from the London-Dublin subsample, we classified N=12 youths reporting both mood- and 
psychotic-related symptoms at 16 from N=154 youths reporting no mood symptoms. The final 
models returned from this analysis had a mean AUC=.709 (95% CI=.706-.713, p<.01) (Figure 2A). 
This model included all brain regions that survived the more liberal threshold of 10 contiguous 
voxels (all regions reported in Table 2), and controlled for psychotic-like experiences’ score at 
age 14 as well as demographic information (i.e., age, sex, handedness and site). All features 
were present in at least 9 folds (out of 10) of the final model. In addition to psychotic-like 
experiences, the most robust brain classifiers were cerebellum activity during processing of 
angry faces and the hippocampus/amygdala activity during neutral faces processing (Table 3A). 
The performance of each domain on its own (i.e., brain activity vs psychotic-like experiences) is 
displayed in Fig S1. We could not significantly classify youth with mood only symptoms (N=80) 
from the other two groups (i.e. mood and psychotic symptoms group, no mood symptoms 
group) (AUC=.532, 95% CI=.525-.539, p=.36; AUC=.453, 95% CI=.450-.456, p=.90 respectively).  
In the second prediction analyses, using the full IMAGEN sample, we classified N=72 youths 
reporting both mood- and psychotic-related symptoms at age 16 from N=673 youths reporting 
no mood symptoms and from N=451 youths with mood symptoms only. The final models 
returned from this analysis had a mean AUC=.633 (95% CI=.630-.636, p<.0001) and AUC=.615 
(95% CI=.614-.617, p=.001) respectively (Figure 2B, 2C). This model included all brain regions 
that survived the more liberal threshold of 10 contiguous voxels, and controlled for internalizing 
and externalizing behaviors, cigarette, alcohol and cannabis use, as well as demographic 
information (i.e. puberty development index, handedness, age, sex and site). When classifying 
the mood and psychotic symptoms group relative to the no mood symptoms group, only the 
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following features: internalizing and externalizing behaviors, cigarette and cannabis use, 
hippocampus/amygdala and cerebellum activity during neutral faces processing as well as 
cerebellum activity during angry faces processing were present in at least 9 folds of the final 
model (Table 3B). However, when classifying the mood and psychotic group relative to the 
mood only group, all features were present in at least 9 folds of the final model, with cerebellum 
activity during angry faces processing, fusiform activity during anticipation of reward, 
internalizing behaviors, cigarette and cannabis use, and hippocampus/amygdala activity during 
neutral face processing making the strongest contribution to group classification (Table 3C).  
Finally, we classified N=451 individuals with mood symptoms only from N=673 individuals 
reporting no mood symptoms with a mean AUC=.553 (95% CI=.552-.553, p=.002) barely better 
than chance (Figure 2D). All features, except the dlPFC activity during failed response inhibition, 
were present in at least 9 folds of the final model. The most important classifiers were 
internalizing and externalizing behaviors, cannabis use, reduced activity from the cerebellum 
during neutral faces processing, puberty development scale, and site (Table 3D).  
 
DISCUSSION 
At age 14, across the brain networks implicated in emotion processing, response inhibition and 
reward anticipation, the cluster-corrected markers of psychotic-like experiences included an 
increased response from the hippocampus/amygdala during processing of neutral material as 
well as reduced activity from the dlPFC during failed inhibition. Of note, hyperactivity from the 
hippocampus/amygdala during the processing of neutral faces further discriminated at 2-year 
follow-up individuals with mood- and psychotic-related symptoms relative to the other groups 
in both the London-Dublin subsample and the full IMAGEN sample, even when controlling for 
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baseline psychotic-like experiences as well as cannabis and cigarette use. The cross-validation 
models best discriminated the mood and psychotic group from the no mood symptoms group in 
comparison to the mood only group from the no mood symptoms group. 
One of the most replicated neural markers of psychosis and high-risk states is hypofunctioning 
of PFC and dlPFC during executive functioning (32). Our results support findings from other 
community-based studies of youth reporting psychosis-spectrum symptoms showing reduced 
PFC activity during working memory and response inhibition tasks (9, 23). However, the activity 
of the dlPFC during the Stop-Signal task was a weak brain classifier for adolescents reporting 
both mood and psychotic symptoms relative to the other groups. A possible explanation might 
be that reduced dlPFC activation is not directly related to positive or mood symptoms, but more 
to disorganized symptoms or cognitive deficits (which were not assessed by our screening tools) 
(9, 33). Consequently, dlPFC alterations would appear to be a promising neuro-functional 
marker of the clinical risk for psychosis when, in addition to positive and negative symptoms, 
significant cognitive impairments are observed; not of youth reporting psychotic-like 
experiences prior to a cognitive decline. It is worth mentioning that the use of a working 
memory task instead of response inhibition could have yielded more significant dlPFC results 
considering that working memory paradigms, in comparison to Stroop tasks or Go-Nogos, 
consistently elicit a more widespread loci of significant activation in the dLPFC and anterior 
cingulate cortex in both healthy controls and schizophrenia patients (11).  
The current exploratory study stresses the importance of an observed increased activity in the 
limbic network in the extended psychosis phenotype. Both fMRI and perfusion studies have 
highlighted increased hippocampal activity at rest and across cognitive tasks in clinically at-risk 
individuals (32, 34). Interestingly, Schobel et al. (35) demonstrated that baseline 
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hypermetabolism of the hippocampus in clinical high-risk individuals is directly related to a 
subsequent volume loss (via a hyperglutamatergic state); thereby supporting the heightened 
hippocampus activity as a highly promising early vulnerability marker to psychotic disorders. In 
the context of emotion processing, a recent meta-analysis showed that the apparent deficit in 
amygdala activity observed in individuals with a psychotic disorder during the viewing of 
negative material may be explained by an elevated amygdala response to neutral material (15). 
These findings have led some authors to propose that abnormalities in salience attribution 
might be core to the extended psychosis phenotype, rather than stress reactivity, per se (36). 
Thus, the increased neural response to neutral information may reflect an atypical assignment 
of motivational salience to these stimuli (37). Results from other cognitive studies showing an 
impaired decoding of facial expressions in patients with psychosis and high-risk populations 
further suggest that the abnormal neural activity in the current study might be due to an 
erroneous identification of neutral faces specifically. For instance, children and adolescents 
reporting psychotic-like experiences over-attribute significance (i.e. negative valence) to neutral 
faces (38). Considering that impaired emotion recognition is linked to declining social 
functioning in high-risk populations (39), it represents a potential target for psychosis symptoms 
prevention strategies for at-risk youth, prior to subsequent impaired social functioning. 
Considering that cerebellar activity significantly contributed to the classification of youth with 
mood- and psychotic-related symptoms relative to the other groups even in the absence of a 
marked alteration in individuals reporting psychotic-like experiences, its role in emotion 
processing in the psychosis-spectrum remains elusive but deserves to be clarified in the future. 
No cluster-corrected activity difference between 14-year olds with and without psychotic-like 
experiences were observed during reward anticipation. Even when using a more liberal cluster 
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threshold, significant activity related to reward anticipation did not robustly contribute to 
discriminate the groups at age 16. These findings are inconsistent with recent fMRI studies 
showing a blunted response from the ventral striatum during reward processing in psychosis 
and high-risk individuals (18, 40). A possible explanation for this negative result may be 
explained by Radua et al.’s findings of a negative correlation between striatal activity and the 
severity of negative symptoms in both patients and individuals at clinical risk for psychosis (18). 
Here, only positive experiences/symptoms were assessed.  
Limitations 
The use of an extended risk phenotype (i.e. youths self-reporting psychotic-like experiences) 
may constitute both a strength and weakness. While it might be too liberal to predict 
vulnerability to specific disorders, particularly those with very low prevalence, one advantage of 
this approach is that it might capture a dimension of vulnerability that is implicated in a number 
of different psychopathological outcomes. The current study also did not investigate 
interactions with family, substance misuse and genetic data, which might further clarify how this 
extended phenotype is implicated in future psychiatric outcomes. Another potential limitation 
to the study is that the use of the bipolar module, at age 16, may have under-estimated the 
emergence of psychotic symptoms in the no mood symptoms group. However, the prevalence 
of psychotic symptoms is low at the end of adolescence (e.g. 5-7%) (1). Finally, the timeframe 
for studying outcomes was relatively brief and might predate the typical age of onset of 
psychotic disorders, however, this might also be considered a strength, as we were able to 
detect relevant brain-related abnormalities before psychotic experiences begin to cause 
significant functional and cognitive impairment, substance misuse and require medical 
intervention.   
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Conclusion 
The results of the present study suggest that an aberrant neural response to non-salient stimuli 
may be an important early vulnerability marker for psychosis, at least in the context of mood 
fluctuations. These findings might help to guide early intervention strategies for at-risk youth. It 
has yet to be determined whether individual differences in emotional reactivity to non-salient 
stimuli can be modified in young adolescents and whether such modifications have any clinical 
significance for high-risk youth.  
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FIGURES LEGENDS 
Figure 1. Cluster-corrected activation differences between 14-year olds with (N=27) and without 
(N=135) psychotic-like experiences.  
Abbreviations: PLEs, Psychotic-like experiences. 
Only cluster-corrected activations are shown in the maps. Bar graphs refer to standard 
deviations (SD).  
 
Figure 2. Receiver-operating characteristics (ROC) curves 
A, ROC of age 16 classification between youth from the London-Dublin subsample with mood 
and psychosis symptoms and those with no mood symptoms 
B, ROC of age 16 classification between youth from the full sample with mood and psychosis 
symptoms and those with no mood symptoms 
C, ROC of age 16 classification between youth from the full sample with mood and psychosis 
symptoms and those with mood symptoms only 
D, ROC of age 16 classification between youth from the full sample with mood symptoms only 
and those with no mood symptoms 
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Table 1. Demographic, substance use and clinical characteristics of the groups at 14 years old 
(baseline).  
Abbreviations: SD, standard deviation; PLEs, Psychotic-like experiences.  
a All p-values in the table are 2-tailed, uncorrected. 
b Unless specified by b, t-tests were used for comparing group means. When specified by b, Chi-
squared tests were used to compare proportions for categorical variables. 
  
Characteristics 
PLEs group 
(N=27) 
Control group 
(N=135) 
P Valuea 
Demographic    
Sex: female, (%)b 64.3% 65.2% .93 
Age at testing, mean (SD) 14.26 (0.31) 14.35 (0.38) .24 
Imaging site: London, (%)b 57.1% 64.4% .47 
Right handed, (%)b 92.9% 91.0% .88 
Puberty status, mean (SD) 3.73 (0.72) 3.69 (0.69) .77 
Cognition    
Verbal IQ, mean (SD) 107.28 (13.64) 110.25 (13.43) .31 
Abstract reasoning IQ, mean (SD) 106.60 (16.70) 107.34 (14.04) .82 
Substance use    
Cigarette use, mean (SD) 0.43 (1.17) 0.40 (1.18) .92 
Alcohol use, mean (SD) 2.25 (1.84) 1.90 (1.84) .37 
Cannabis use, mean (SD) 0.00 (0.00) 0.08 (0.48) .36 
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Table 2. Regions showing group differences in the fMRI contrasts 
 
Regions Direction T-Value 
MNI 
coordinates 
Voxels 
Effect size 
(Cohen’s d) 
x y z 
Faces Task, Angry > Neutral contrast  
Cerebellum L CT > PLEs 3.58 -3 -79 -38 10  
Faces Task, Neutral > Reference 
contrast 
       
Hippocampus/amygdala R PLEs > CT 4.68 30 -13 -17 25* 0.987 
Middle temporal gyrus R | Temporal 
pole 
PLEs > CT 4.19 54 5 -20 10  
Cerebellum L PLEs > CT 3.88 -42 -49 -32 11  
Inferior frontal gyrus, orbital part L CT > PLEs 4.18 -30 32 -20 13  
Lingual gyrus R CT > PLEs 4.15 21 -55 -5 12  
Fusiform gyrus L CT > PLEs 4.14 -33 -31 -17 12  
Stop-Signal Task, Stop success > Baseline  
No significant activation difference  
Stop-Signal Task, Stop failure > Baseline  
Middle frontal gyrus R CT > PLEs 4.65 30 38 40 37* 0.980 
Caudate nucleus L CT > PLEs 4.41 -15 8 19 10  
Monetary Incentive Delay Task, Anticipation large win > No win  
Anterior/middle cingulate gyrus R PLEs > CT 3.77 3 29 31 13  
Fusiform gyrus L CT > PLEs 4.40 -27 -37 -23 15  
 
Abbreviations: MNI, Montreal Neurological Institute space; L, left; R, right; CT, Control group 
reporting no significant psychotic-like experiences; PLEs, Group reporting significant psychotic-
like experiences. 
*Cluster presented are corrected at p<0.05 according to AFNI 3dClustSim. Other brain regions 
presented survived the more liberal cluster threshold of ≥ 10 contiguous voxels. 
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Table 3. Beta weights for prediction of age 16 outcome 
A 
Predictors Mean Betas 
Demographic information 
Age 0.101 
Sex (male) -0.079 
Site 0.105 
Handedness (right-handed) -0.182 
Symptoms 
Psychotic-like experiences at baseline 0.577 
Brain ROIs 
dlPFC during failed inhibition 0.021 
Caudate during failed inhibition -0.088 
Cerebellum during angry faces processing 0.276 
Hippocampus/amygdala during neutral faces processing 0.253 
Middle temporal during neutral faces processing 0.070 
Cerebellum during neutral faces processing -0.234 
Inferior frontal during neutral faces processing -0.126 
Lingual gyrus during neutral faces processing -0.142 
Fusiform gyrus during neutral faces processing -0.077 
ACC/MCC during anticipation of reward 0.066 
Fusiform gyrus during anticipation of reward -0.216 
 
B 
Predictors Mean Betas 
Demographic and substance use information 
Cannabis use in the previous year 0.137 
Lifetime cigarette use  0.150 
Symptoms 
Internalizing behaviors 0.307 
Externalizing behaviors 0.084 
Brain ROIs 
Cerebellum during angry faces processing 0.092 
Hippocampus/amygdala during neutral faces processing 0.073 
Cerebellum during neutral faces processing -0.090 
 
C 
Predictors Mean Betas 
Demographic and substance use information 
Age 0.027 
Sex (male) 0.188 
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Site 0.023 
Handedness (right-handed) -0.020 
Puberty development score 0.077 
Cannabis use in the previous year 0.250 
Lifetime cigarette use 0.268 
Alcohol use in the previous year -0.171 
Symptoms 
Internalizing behaviors 0.297 
Externalizing behaviors 0.098 
Brain ROIs 
dlPFC during failed inhibition 0.100 
Caudate during failed inhibition -0.142 
Cerebellum during angry faces processing 0.317 
Hippocampus/amygdala during neutral faces processing 0.192 
Middle temporal during neutral faces processing 0.100 
Cerebellum during neutral faces processing -0.066 
Inferior frontal during neutral faces processing -0.101 
Lingual gyrus during neutral faces processing -0.158 
Fusiform gyrus during neutral faces processing -0.135 
ACC/MCC during anticipation of reward -0.005 
Fusiform gyrus during anticipation of reward -0.306 
 
D 
Predictors Mean Betas 
Demographic information 
Age -0.024 
Sex (male) -0.053 
Site -0.097 
Handedness (right-handed) 0.041 
Puberty development score 0.096 
Cannabis use in the previous year 0.140 
Lifetime cigarette use -0.057 
Alcohol use in the previous year 0.058 
Symptoms 
Internalizing behaviors 0.154 
Externalizing behaviors 0.100 
Brain ROIs 
Caudate during failed inhibition 0.062 
Cerebellum during angry faces processing -0.083 
Hippocampus/amygdala during neutral faces processing -0.029 
Middle temporal during neutral faces processing -0.025 
Cerebellum during neutral faces processing -0.132 
Inferior frontal during neutral faces processing 0.036 
Lingual gyrus during neutral faces processing 0.071 
Fusiform gyrus during neutral faces processing 0.039 
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ACC/MCC during anticipation of reward 0.025 
Fusiform gyrus during anticipation of reward 0.088 
Abbreviations: dlPFC, dorsolateral prefrontal cortex; ACC/MCC, anterior/middle cingulate 
cortex. 
A, Mean beta weights (averaged over 10 outer folds) of the features that were present in at 
least 9 folds (out of 10) of the final model for classification of the mood and psychotic symptoms 
group versus the no mood symptoms group in the London-Dublin subsample. B, Mean beta 
weights (averaged over 10 outer folds) of the features that were present in at least 9 folds (out 
of 10) of the final model for classification of the mood and psychotic symptoms group versus the 
no mood symptoms group in the full IMAGEN sample. C, Mean beta weights (averaged over 10 
outer folds) of the features that were present in at least 9 folds (out of 10) of the final model for 
classification of the mood and psychotic symptoms group versus the mood symptoms only 
group in the full IMAGEN sample. D, Mean beta weights (averaged over 10 outer folds) of the 
features that were present in at least 9 folds (out of 10) of the final model for classification of 
the mood symptoms only group versus the no mood symptoms group in the full IMAGEN 
sample. 
